Buprenorphine is combined with naloxone to discourage misuse by injection. When taken as directed, dissolved under the tongue, the naloxone component is barely absorbed into the body and has almost no effect. But if someone crushes and injects the tablet or film, the naloxone enters the bloodstream fully and triggers immediate, intense withdrawal symptoms. This design creates a built-in deterrent while preserving buprenorphine’s therapeutic benefits for treating opioid dependence.
How the Combination Works Under the Tongue
The key to this formulation is a large gap in how well each drug is absorbed through the tissue under the tongue. Buprenorphine has a sublingual bioavailability of 35% to 55%, meaning a meaningful portion reaches the bloodstream. Naloxone, by contrast, has less than 10% sublingual bioavailability. So when you dissolve the medication as prescribed, you get a therapeutic dose of buprenorphine and a negligible amount of naloxone.
Timing reinforces this difference. Buprenorphine has a half-life of about 32 hours, so it stays active in the body for a long time. Naloxone’s half-life is roughly 1 hour. Even the small amount of naloxone that does get absorbed sublingually drops off quickly and never reaches levels high enough to interfere with treatment. The standard formulation uses a 4:1 ratio, typically 4 mg of buprenorphine to 1 mg of naloxone, calibrated so the naloxone is pharmacologically invisible during normal use.
What Happens if the Medication Is Injected
Injecting the combination changes everything. Naloxone is an opioid antagonist, meaning it blocks opioid receptors without activating them. When it enters the bloodstream directly through injection, its full dose reaches the brain within minutes. For someone who is physically dependent on opioids, this rapidly displaces whatever opioid is sitting on their receptors and triggers precipitated withdrawal: sudden onset of nausea, vomiting, cramping, sweating, anxiety, and intense discomfort.
This effect is intentional. The prospect of immediate, severe withdrawal acts as a powerful disincentive against injecting the medication. Buprenorphine itself also has properties that limit misuse. It is a partial opioid agonist, meaning it activates opioid receptors only partially. Even at higher doses, it produces a limited “high” compared to full agonists like heroin or fentanyl. The naloxone adds another layer of protection on top of that built-in ceiling.
Snorting the medication also partially defeats the sublingual design. Insufflation raises naloxone’s bioavailability to around 30%, triple what sublingual dosing produces. That higher absorption increases the chance of uncomfortable withdrawal effects, making this route less appealing as well.
Buprenorphine’s Built-In Safety Ceiling
Beyond the naloxone question, buprenorphine itself was chosen for opioid dependence treatment partly because of a pharmacological ceiling effect on respiratory depression, which is the primary way opioid overdoses kill. Research has shown that doubling the dose of buprenorphine does not produce a corresponding increase in respiratory depression. In one study, participants receiving 0.2 mg and those receiving 0.4 mg showed nearly identical reductions in breathing rate, with no statistically significant difference between the groups. Notably, this ceiling applies to respiratory effects but not to pain relief, meaning the drug can still provide increasing analgesia at higher doses without proportionally increasing the danger of slowed breathing.
This ceiling effect makes buprenorphine substantially harder to fatally overdose on compared to full opioid agonists like methadone. Adding naloxone to the formulation addresses the separate problem of people dissolving tablets and injecting them to bypass the partial-agonist limitations and chase a stronger, faster effect.
Why Some Patients Get Buprenorphine Alone
Not everyone receives the combination product. Buprenorphine monotherapy (without naloxone) is preferred during pregnancy and breastfeeding. The concern is straightforward: naloxone’s effects on developing fetuses have not been well studied, and if a pregnant patient were to misuse the combination product by injection, the naloxone could trigger withdrawal in both the mother and the fetus. Fetal withdrawal carries serious risks, so clinicians avoid that possibility by prescribing buprenorphine alone.
This does create a tradeoff. Monotherapy tablets carry a higher potential for diversion and misuse because they lack the naloxone deterrent. In practice, prescribers weigh this risk against the known dangers of naloxone exposure during pregnancy and consistently favor monotherapy for this population.
How Well the Deterrent Actually Works
The real-world picture is more complicated than the pharmacology might suggest. An international review of diversion studies found that people do still inject the combination product. In a Finnish study of 176 needle exchange participants, 68% reported having tried injecting buprenorphine/naloxone intravenously, but 80% of them described the experience as negative. In Malaysia, when the combination product replaced buprenorphine monotherapy, people who continued injecting reported developing withdrawal symptoms, which was associated with increased use of other drugs like benzodiazepines and more syringe sharing.
These findings highlight that adding naloxone does not eliminate misuse entirely, but it does make injection less rewarding and more unpleasant. The deterrent works best as one part of a broader treatment approach that includes counseling, regular check-ins, and stable access to medication.
Film vs. Tablet Formulations
The combination is available as both sublingual tablets and thin dissolvable films. Both use the same 4:1 buprenorphine-to-naloxone ratio. Films dissolve faster due to their thin, flexible structure, and they may provide slightly better absorption at lower doses. The original sublingual tablets were first approved by the FDA in October 2002. Films were developed later partly to improve convenience and reduce the chance of diversion, since they are harder to crush and prepare for injection. No head-to-head clinical trials have definitively shown one form to be more effective than the other for treatment outcomes, so the choice often comes down to patient preference and insurance coverage.